Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial

References

• Kasturi S, Sammaritano LR. Corticosteroids in lupus. Rheum D is Clin North Am 2016;42:47–62.
   PubMed Web of Science ®Google Scholar
• Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am 2016;42:157–76.
   PubMed Web of Science ®Google Scholar
• ICH Harmonised Tripartite Guideline. Post-approval safety data management: definitions and standards for expedited reporting E2D. Current Step 4 version, 2003 (www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf). Accessed 1 June 2017.
   Google Scholar
• Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955–9.
   PubMed Web of Science ®Google Scholar
• Thamer M, Hernán MA, Zhang Y, Cotter D, Petri M. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560–4.
   PubMed Web of Science ®Google Scholar
• Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801–8.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009;11:109.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777–87.
   PubMed Web of Science ®Google Scholar
• van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkers MA, Buttgereit F, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010;69:1015–21.
   PubMed Web of Science ®Google Scholar
• Sheane BJ, Gladman DD, Su J, Urowitz MB. Disease outcomes in corticosteroid-naïve patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2017;69:252–6.
   PubMed Web of Science ®Google Scholar
• Nisen P, Rockhold F. Access to patient-level data from GlaxoSmithKline clinical trials. N Engl J Med 2013;369:475–8.
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–430.
   PubMed Web of Science ®Google Scholar
• MedDRA Introductory Guide Version 19.0, 2016. (www.meddra.org/sites/default/files/guidance/file/intguide_19_0_english.pdf). Accessed 1 June 2017.
   Google Scholar
• Wei LQ, Liang YG, Zhao Y, Liang HT, Qin DC, She MC. Efficacy and safety of belimumab plus standard therapy in patients with systemic lupus erythematosus: a meta-analysis. Clin Ther 2016;38:1134–40.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Petri M, Wallace DJ, Roth DA, Molta CT, Hammer AE, et al. Cumulative corticosteroid dose over fifty-two weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials. Arthritis Rheumatol 2016;68:2184–92.
   PubMed Web of Science ®Google Scholar
• Shah M, Chaudhari S, McLaughlin TP, Kan HJ, Bechtel B, Dennis GJ, et al. Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus. Clin Ther 2013;35:486–97.
   PubMed Web of Science ®Google Scholar
• Barbour SY. Corticosteroids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 2012;10:493–9.
   PubMed Web of Science ®Google Scholar
• Calvo-Alén J, Toloza SM, Fernández M, Bastian HM, Fessler BJ, Roseman JM, et al. LUMINA study group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005;52:2060–8.
   PubMed Web of Science ®Google Scholar
• Gordon C, Li CK, Isenberg DA. Systemic lupus erythematosus. Medicine 2010;38:73–80.
   Google Scholar
• O’Neill S, Cervera R. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2010;24:841–55.
   PubMed Web of Science ®Google Scholar
• Touma Z, Urowitz MB, Ibanez D, Gladman DD. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol 2014;41:688–97.
   PubMed Web of Science ®Google Scholar
• Abou Zahr Z, Fang H, Magder LS, Petri M. Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort. Lupus 2013;22:697–701.
   PubMed Web of Science ®Google Scholar
• Abeles M, Urman JD, Rothfield NF. Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Intern Med 1978;138:750–4.
   PubMedGoogle Scholar
• Mont MA, Pivec R, Banerjee S, Issa K, Elmallah RK, Jones LC. High-dose corticosteroid use and risk of hip osteonecrosis: meta-analysis and systematic literature review. J Arthroplasty 2015;30:1506–12.
   PubMed Web of Science ®Google Scholar
• Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA, Moran MA, Ruiz-Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2014;53:1470–6.
   PubMed Web of Science ®Google Scholar
• Al Sawah S, Zhang X, Zhu B, Magder LS, Foster SA, Iikuni N, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus – the Hopkins Lupus Cohort. Lupus Sci Med 2015;2:e000066.
   PubMed Web of Science ®Google Scholar